drugset / Trial / NCT04404569
Continued Treatment for Participants Enrolled in Studies of BXQ-350
Phase 1
Terminated
5 enrolled
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.
Timeline
- Start
- 2020-06-08
- Primary completion
- 2024-09-23
- Completion
- 2024-09-23
Outcome
Outcome not reported
Stopped (Enrollment): “Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAPOSIN C (NON-GLYCOSYLATED) | Other / unclassified | 2.4 mg/kg | Intravenous |
| Subject | SAPOSIN C (NON-GLYCOSYLATED) | Other / unclassified | 3.2 mg/kg | Intravenous |